Dinani apa ngati iyi ndi nkhani yanu yosindikiza!

Myeloid Leukemia: Chithandizo Chatsopano Chopambana

Ascentage Pharma, kampani yapadziko lonse ya biopharmaceutical yomwe ikupanga mankhwala atsopano a khansa, matenda a chiwindi a B (CHB), ndi matenda okhudzana ndi zaka, ndi Innovent Biologics, Inc. ("Innovent"), kampani yapamwamba padziko lonse lapansi ya biopharmaceutical yomwe imapanga, kupanga. ndikugulitsa mankhwala apamwamba kwambiri ochizira matenda a oncology, metabolic, autoimmune ndi matenda ena akuluakulu, akulengeza pamodzi kuti wolemba mankhwala olverembatinib wa ku Guangzhou HealthQuest Pharma Co., Ltd., Inc., wothandizidwa ndi Ascentage Pharma, ali ndi adavomerezedwa ndi China National Medical Products Administration (NMPA) pochiza odwala akuluakulu omwe ali ndi tyrosine kinase inhibitor (TKI)-resistant phase chronic myeloid leukemia (CML-CP) kapena accelerated-phase CML (CML-AP) yomwe ili ndi T315I kusintha monga kutsimikiziridwa ndi kuyesa kovomerezeka kwa matenda (chizindikiro chomwe sichinavomerezedwe ku US).

Sangalalani, PDF ndi Imelo

Yopangidwa ndi Ascentage Pharma mothandizidwa ndi pulogalamu ya National Major New Drug Discovery and Manufacturing, olverembatinib ndi mankhwala omwe angakhale abwino kwambiri omwe angagulidwe pamsika wa China ndi Innovent ndi Ascentage Pharma, kuti apindule odwala ambiri ndi awo. mabanja. Monga m'badwo woyamba wachitatu waku China wa BCL-ABL TKI wopangidwira chithandizo cha CML chosamva TKI, kuvomereza kumeneku kumadzaza kusiyana kofunikira kwamankhwala mu T315I-mutant CML, ndipo ndi chizindikiro chachikulu chosonyeza kuti Ascentage Pharma yalowa bwino mugawo lazamalonda.

Chivomerezo ichi cha olverembatinib chimachokera ku zotsatira za maphunziro awiri ofunika kwambiri a Phase II - kafukufuku wa HQP1351CC201 ndi kafukufuku wa HQP1351CC202. Zotsatirazi zikuwonetsa kuti olverembatinib ndi yothandiza komanso yololera bwino kwa odwala omwe ali ndi CML-CP ndi CML-AP, ndipo kuthekera ndi kuya kwakuya kwamankhwala kumayembekezeredwa kuwonjezeka ndi nthawi yayitali ya chithandizo.

CML ndi vuto la hematologic la maselo oyera a magazi. Kukhazikitsidwa kwa BCR-ABL TKIs kwasintha kwambiri kasamalidwe kachipatala ka CML. Komabe, kupeza kukana kwa TKIs kumakhalabe vuto lalikulu pochiza CML. Kusintha kwa BCR-ABL tyrosine kinase kumayimira njira yofunika kwambiri yopezera kukana mankhwala; T315I, yomwe ndi masinthidwe ambiri osamva mankhwala, amapezeka pafupifupi 25% ya odwala omwe ali ndi CML yosamva mankhwala. Odwala omwe ali ndi T315I-mutant CML sagonjetsedwa ndi zoletsa za BCR-ABL za m'badwo woyamba ndi wachiwiri, motero akupereka kufunikira kwachipatala kosayembekezereka kwa chithandizo choyenera.

Sangalalani, PDF ndi Imelo

Ponena za wolemba

Linda Hohnholz, mkonzi wa eTN

Linda Hohnholz wakhala akulemba ndi kusintha zolemba kuyambira pomwe anayamba ntchito. Iye wagwiritsa ntchito chilakolako chobadwachi m'malo ngati Hawaii Pacific University, Chaminade University, Hawaii Children's Discovery Center, ndipo tsopano TravelNewsGroup.

Siyani Comment